

Age-related effects and gender differences in Japanese healthy controls for [¹²³I] FP-CIT SPECT

Hideo Yamamoto¹ · Shinichi Arimura¹ · Atsushi Nakanishi¹ · Yasushi Shimo³ · Yumiko Motoi^{2,3} · Koichi Ishiguro³ · Koji Murakami¹ · Nobutaka Hattori^{2,3} · Shigeki Aoki¹

Received: 26 January 2017 / Accepted: 29 March 2017 / Published online: 5 April 2017
© The Japanese Society of Nuclear Medicine 2017

Abstract

Objective Dopamine transporter (DAT) imaging with [¹²³I]FP-CIT (DaTSCAN) is a widely used diagnostic tool for Parkinsonism and dementia. Since it was approved by the Japanese Ministry of Health, Labor, and Welfare in 2013, there have been no articles focusing on a Japanese normal population. The aim of this study was to examine the effect of aging and gender on DAT availability in Japanese people.

Methods SPECT imaging of 30 healthy Japanese controls (17 males, 13 females; range 50–86 years, mean 70 years) was performed. SPECT images were reconstructed using a three-dimensional order subset expectation maximization (OSEM) algorithm with correction of the point spread function and scatter correction, without attenuation correction. The specific binding ratio (SBR) was calculated by DATview software. Statistical analyses were performed using linear regression analysis, analysis of variance, and multiple comparison analysis.

Results A strong correlation between the SBR and age was observed. The correlation coefficient in males and females were -0.566 and -0.502 , respectively. The analysis of variance revealed that aging led to a decline of the SBR, and a significant difference ($p=0.005$) was observed among generations. Gender also affected the SBR, and there was a significant difference between males and females ($p=0.036$). The SBR in females was higher than in males. Consequently, the multiple comparison revealed a significant difference between 50s and 70s ($p=0.015$) and 50s and 80s ($p=0.006$).

Conclusions This is the first [¹²³I]FP-CIT SPECT study on subjects with normal dopamine function in Asian countries. This study provides a database of [¹²³I]FP-CIT SPECT in Japanese healthy controls. Higher DAT availability was found in women than in men. An average age-related decline in DAT availability of 8.9% was found in both genders. The data collected in this study would be helpful for Japanese physicians to make a differential diagnosis in Parkinsonian syndrome.

The registration identification number for this study is UMIN000018045.

Electronic supplementary material The online version of this article (doi:10.1007/s12149-017-1168-1) contains supplementary material, which is available to authorized users.

✉ Yumiko Motoi
motoi@juntendo.ac.jp

- ¹ Department of Radiology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
- ² Diagnosis, Prevention and Treatment of Dementia, Juntendo University Graduate of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
- ³ Department of Neurology, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan

Keywords [¹²³I]FP-CIT SPECT · Japan · Normal database · Dopamine transporter

Introduction

Single photon emission computed tomography (SPECT) imaging of the dopamine transporter (DAT) is widely used to assess presynaptic dopamine neuronal dysfunction in Parkinsonian syndrome and dementia with Lewy bodies (DLB). The European Medicines Agency (EMA) approved the agent [¹²³I]FP-CIT under the name DaTSCAN in

2000 [1]. The US Food and Drug Administration (FDA) approved it under the trade name DaTscan in 2011 [2]. In Asia, it was first approved by the Japanese Ministry of Health, Labor, and Welfare in 2013.

In European countries, several studies on [^{123}I]FP-CIT SPECT in normal human populations have been reported [3–11]. All of them showed a progressive decline of DAT expression with aging. Some of them reported a gender difference, with higher striatal binding in women compared with men, while others did not find this difference. As far as we know, there have been no reports of this kind in Asian countries. In this study, we sought to evaluate the effect of both age and gender on [^{123}I]FP-CIT binding to dopamine transporters in a Japanese population.

Materials and methods

Subjects

Subjects were 30 healthy controls (17 males, 13 females; range 50–86 years, mean 70 years) who underwent [^{123}I]FP-CIT SPECT imaging. The study obtained the approval of ethical review board of our institution and was performed on the basis of informed consent from the subjects. All subjects were Japanese, applied for participation voluntarily, and understood the purpose of this study. Eligibility criteria included: healthy male and female Japanese volunteers (range 40–89 years); subjects required to attend examinations at an appointed date; a total score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part III, which was performed 3 months before and after agreement was 0 (60 years or younger) or less than 5 (61 years or over); magnetic resonance imaging (MRI) images, which were performed 3 months before and after agreement, were normal for the age (allowed atrophy for age and small lacunar infarction); consent for the study was provided in a document. On the other hand, exclusion criteria included: alcoholism or a history of alcoholism; pregnancy, possible pregnancy, or lactating woman; epilepsy or history of epilepsy; an education history of 6 years or below; a history of neuropsychiatric disorder affecting cognitive brain function; severe complications (hepatopathy, nephropathy, and endocrine diseases);

the use the drugs that influence the accumulation of [^{123}I]FP-CIT in the brain, antidepressants, psychotropic agents, sedatives (including an anti-anxiety drugs), cocaine hydrochloride, mazindol, methylphenidate hydrochloride, sertraline hydrochloride, and serotonin reuptake inhibitors.

Smoking data

All subjects were interviewed about smoking history and classified into three categories: non-smokers ($n=23$), ex-smokers ($n=4$) and active-smokers ($n=3$), as shown in the Table 1. The number of cigarettes smoked per day for active-smokers and packs in lifetime for active and ex-smokers were registered.

SPECT imaging

[^{123}I]FP-CIT (167 MBq) was injected intravenously as a bolus in a volume of 2 ml. Scans were obtained at 3 h after tracer injection, and the total scan time was 30 min. [^{123}I]FP-CIT SPECT imaging was performed using Siemens SYMBIA E with a low-middle energy general purpose collimator (LMEGP). The acquisition parameters were as follows: rotational radius fixed for all SPECT studies 15 cm; matrix 128×128 ; angular sampling 3° (360° rotation), and a pixel size of 3.3 mm. The photo-peak imaging window ($158 \text{ keV} \pm 10\%$) and 2 scatter energy windows (below $142 \text{ keV} - 7\%$, above $173 \text{ keV} + 7\%$) were acquired.

As reported previously, reconstruction parameters effect image quality and quantitative value in [^{123}I]FP-CIT SPECT imaging [7, 12], although Varrone et al. described that the effect of attenuation correction on the SBR was small [11]. Matsumoto et al. reported that the optimal reconstruction parameters for order subset expectation maximization (OSEM) with resolution recovery, scatter, and attenuation correction have the potential to improve the performance and the image quality of [^{123}I]FP-CIT SPECT in comparison with the FBP reconstruction [13]. Therefore, we confirmed the optimal reconstruction parameters for OSEM, and validated the effects of three OSEM reconstruction methods: without attenuation correction and scatter correction (NOACSC), with only attenuation correction (AC) and with attenuation correction and scatter correction

Table 1 Age and smoking habits for 30 healthy volunteers

	Number	Mean age \pm SD (range)	Current average number of cigarettes per day \pm SD (range)	Total number of packages in lifetime mean (range)
Non-smokers	23 (12 males)	71.3 \pm 11.7 (51–86)	0	0
Ex-smokers	4 (2 males)	71.3 \pm 9.7 (58–84)	0	4084 (457–10,950)
Active smokers	3 (3 males)	60.3 \pm 7.3 (50–66)	14.3 (10–20)	9156 (5475–11,315)

(ACSC). The count converged with an update number over 60 and the coefficient of variance (CV) continuously increased with the update number in each method. In the update number of 60, the striatum-background count ratio showed the approximate truth value for NOACSC. However, those indicated were 1.5 times higher than the truth value for ACSC and slightly higher for AC. Accordingly, SPECT images were reconstructed using an OSEM algorithm with 6 iterations and 10 subsets of 120 projections. Three-dimensional OSEM reconstructions were performed with correction of point spread function and NOACSC. Post-filtering was applied using Gaussian filter at 6.6 mm.

The specific binding ratio (SBR) was calculated using the ratio of specific binding to nonspecific accumulation of [¹²³I]FP-CIT in the striatum [14]. The SBRs were calculated using DATview software (AZE, Tokyo). The striatal region was defined from trans axial images within 44 mm thickness of the template volume of interest (VOI), and the reference region was semi-automatically defined from the non-specific accumulation in the whole brain, excluding the striatal region, by count threshold. The SBRs were calculated as follows:

$$SBR = \left(\frac{C_{StrVOI} - C_{per\ pixel\ BG\ VOI} \times \text{Number of pixel}_{StrVOI}}{Vol_{Str}} \right) \frac{1}{C_{per\ pixel\ BG\ VOI}}$$

where C_{StrVOI} is the count of the striatum VOI, $C_{per\ pixel\ BG\ VOI}$ is the count of the reference VOI per pixel, number of $pixel_{StrVOI}$ is number of pixels in the striatum VOI, and Vol_{Str} is the volume of the striatum that is 11.2 ml const. The absolute value of asymmetry index (AI) was obtained using the following formula: $[(R-L)/(R+L)] \times 2 \times 100$, where R and L represent right and left SBR, respectively.

Statistical analysis

The differences in the SBR were evaluated using a one-way analysis of variance (ANOVA) to validate the effects of three categories between non-smokers, ex-smokers and active-smokers. A correlation coefficient was calculated between the SBR and the number of cigarettes per day.

Linear regression analysis was performed to investigate the relationship between age and the SBR in both genders. The Bartlett test was performed to confirm homogeneity of variance, which was required for analysis of variance. The differences in the SBR were evaluated using a two-way factorial ANOVA to validate the effects of 2 variables, age and gender, which affect the SBR. In addition, a multiple comparison using Tukey’s honestly significant difference (HSD) test was performed to investigate the effects of age. Differences between the right and left SBR were evaluated with a paired *t*-test. Statistical analyses were conducted using R version 3.3.0 (R Core Team 2016).

Results

Representative SPECT images of healthy controls aged from 50 to 86 years are shown in Fig. 1. These images show that [¹²³I]FP-CIT binding in the caudate nucleus





Fig. 2 Linear regression analysis of the SBR values obtained in males and females as a function of age

Fig. 1 Representative SPECT images of [¹²³I]FP-CIT in subjects in their 50s, 60s, 70s, and 80s. The pixel intensity of the scaled SPECT image was normalized by the SBR. The SBR image was displayed with predefined color table and upper threshold fixed at SBR = 6



and putamen is likely to decrease with aging. Linear regression analysis between age and SBR is shown in Fig. 2. A strong correlation between the SBR and age was observed. The correlation coefficient in males and females was -0.566 and -0.502 , respectively. The relationship between age and the SBR in males and females is shown in Fig. 3. The average SBR in males was lower than that in females in each generation. The SBRs declined between generations: 13.1% (50–60s), 11.2% (60–70s), and 2.4% (70–80s). An average age-related decline in DAT binding of 8.9% per decade was found. When we assume the cutoff score for the SBR equals the average minus the standard deviation, it was 5.14 in 50s, 4.65 in 60s, 4.63 in 70s, and 4.17 in 80s. p -values of age and gender were greater than 0.05 in the Bartlett-test, therefore variance in each group was equal. Two-way factorial analysis of variance (ANOVA) showed that aging led to a decline in the SBR, and a significant difference ($p=0.005$) was observed among generations. Gender also affected the SBR in the ANOVA, and there was a significant difference between males and females ($p=0.036$). However, an interaction between age and gender was not confirmed ($p=0.740$). From these results, a multiple comparison was conducted (supplementary Fig. 1). Consequently, a significant difference between 50s and 70s ($p=0.015$), and 50s and 80s ($p=0.006$) was confirmed. In contrast, there was no difference in the SBR ($p=0.364$) between the right and left striatal regions in a paired t -test. The correlation coefficients of the AI, ranging from 0.5 to 19.3, in males and females were -0.0895 and 0.0783 , respectively. Moreover, no significant difference was observed among generations ($p=0.811$), between each gender ($p=0.973$) and an interaction between age and gender ($p=0.286$) in the ANOVA (Fig. 4).




Fig. 3 Mean of the SBRs in males and females as a function of age




Fig. 4 Linear regression analysis of the AI values obtained in males and females as a function of age

There was no significant difference ($p=0.46$) between non-smokers, ex-smokers and active-smokers (Fig. 5). Moreover, the correlation was not observed between the number of cigarettes per day and SBR ($r=0.156$) (Supplementary Fig. 2).

Discussion

This is the first [123 I]FP-CIT SPECT study on subjects with normal dopamine function in Asian countries. Our study of a Japanese population demonstrated that women had significantly higher DAT availability than men, and that there was an age-related decrease. An average age-related decline in DAT binding of 8.9% per decade was found between people in their 1950s and 1980s.

The higher age-related decline rate (8.9%) in our study compared with 6.5% in western countries [11] may be associated with the racial difference in the polymorphism of the dopamine transporter gene, *hDAT1*(SLC6A3). A




Fig. 5 Relationship between SBR and number of cigarettes per day

polymorphism involving a variable number of tandem repeats has been reported in the 3' untranslated region of SLC6A3 gene coding for the DAT. This polymorphism has 2 common alleles, designated as 10-repeat and 9-repeat. The frequency of a 10-repeat allele, a dominant allele, was higher in the Japanese than in the Caucasian population while a 9-repeat allele decreased in Japanese participants compared with the Caucasian controls [15]. It was reported that the expressions of DAT mRNA and protein were decreased in the 9-repeat carriers [16]. Therefore, the amount of striatal DAT protein in the Japanese population may be higher than in European countries. DAT knockout mice displayed reduction of age-related locomotor effects and dopamine metabolites in the striatum [17], suggesting that high level of DAT protein could alter aging of dopaminergic systems.

DAT is expressed in the presynaptic axonal terminals of nigrostriatal pathways, and striatal DAT may be associated with nigral dopamine neuronal loss. In a group of autopsy-confirmed cases with Alzheimer's disease, DLB, and Parkinson's disease dementia, [¹²³I]FP-CIT uptake was associated with nigral dopaminergic density [18]. Our analysis of a normal population aged between 50 and 80 years demonstrated that the average age-related decline in the SBR was 8.9% per decade. Previous studies in healthy controls aged between 20 and 80 years reported a 3.6–7.5% decrease in [¹²³I]FP-CIT binding [3–5, 7, 10, 11, 19]. An analysis of autopsied brains from subjects aged from 21 to 91 years revealed that there was a decrease of pigmented neurons in the pars compacta of the substantia nigra at a rate of 4.7% [20]. Therefore, the aging effect of [¹²³I]FP-CIT uptake in the basal ganglia is likely to be attributed to dopaminergic cell number in the substantia nigra.

Our study reported that women had significantly higher DAT availability than men. Studies in western countries have shown higher [¹²³I]FP-CIT binding in women than in men [7, 11, 19], although 2 studies have shown negative findings [8, 19]. The binding of striatal DAT labeled with [³H]GBR 12,935 and substantia nigra DAT mRNA were higher in female rats compared with males [21]. Laboratory studies show that estrogen may play a neuroprotective role. A subcutaneous injection of 17 β -estradiol into male C57Bl/6 male mice increased the number of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta [22]. Estradiol modulates dopamine release via membrane estradiol receptors [23]. Parkinson's disease incidence has been shown to be 1.5 times higher in men than women [24]. The gender difference in DAT availability may reflect a protective effect of estrogen on dopaminergic cells.

The SBR could be estimated too low in patients with enlargement of ventricles or atrophic brains, and can differ with the use different cameras. Quantification of [¹²³I]

FP-CIT SPECT has been shown to be affected by reconstruction strategies, AC, and SC [13, 25, 26]. However, we could minimize the influence of these various factors that affect [¹²³I]FP-CIT SPECT imaging, because all images were able to be obtained with identical imaging parameters in a single institutional study. Another weakness of this study is that the number of subjects was relatively small. Especially, the ratio of females to males was deviated in some generations, including only 2 males in 1950s and 2 females in 1970s and 1980s. Further study using a larger population in multiple centers is needed to establish a Japanese database for clinical trials.

In conclusion, we performed [¹²³I] FP-CIT SPECT analysis for the first time in Japanese healthy controls. The average value minus a standard deviation of the SBR between 50 and 80 years of age was 4.64, which is almost same (4.5) as the cutoff originally proposed [14]. The data collected in this study would be helpful for Japanese physicians to make a differential diagnosis of Parkinsonian syndrome or dementia with Lewy bodies.

Acknowledgements Dr. Yumiko Motoi is an Endowed Associate Professor of Department of Diagnosis, Prevention and Treatment of Dementia that has been sponsored by Nippon Medi-Physics Co. Ltd. She has received research grants from the company. Dr. Koji Murakami and Dr. Nobutaka Hattori have received a speaker honorarium from Nippon Medi-Physics Co. Ltd. Dr. Shigeki Aoki has received research grants and a speaker honorarium from Nippon Medi-Physics Co. Ltd.

Compliance with ethical standards

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent Informed consent was obtained from all individual participants included in the study.

Conflict of interest This research was supported by Nihon Medi-Physics CO., Ltd.

References

1. European Medicines Agency. Prescribing information for DaTSCAN Website. 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000266/human_med_000739.jsp&mid=WC0b01ac058001d124. Accessed 13 Mar 2017.
2. FDA. Prescribing information for DaTscan Website. 2017. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.pdf. Accessed 13 Mar 2017.
3. Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with

- [123I]FP-CIT SPET in healthy volunteers. *Eur J Nucl Med.* 2000;27(7):867–9.
4. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. *Am J Geriatr Psychiatry.* 2002;10(1):36–43.
 5. Best SE, Sarrel PM, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle. *Psychopharmacology (Berl).* 2005;183(2):181–9.
 6. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, et al. Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. *J Nucl Med.* 2005;46(5):745–51.
 7. Eusebio A, Azulay JP, Ceccaldi M, Girard N, Mundler O, Guedj E. Voxel-based analysis of whole-brain effects of age and gender on dopamine transporter SPECT imaging in healthy subjects. *Eur J Nucl Med Mol Imaging.* 2012;39(11):1778–83.
 8. Jakobson Mo S, Larsson A, Linder J, Birgander R, Edenbrandt L, Stenlund H, et al. (1)(2)(3)I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools. *Nucl Med Commun.* 2013;34(10):978–89.
 9. Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. *Eur J Nucl Med Mol Imaging.* 2013;40(4):565–73.
 10. Thomsen G, Knudsen GM, Jensen PS, Ziebell M, Holst KK, Asenbaum S, et al. No difference in striatal dopamine transporter availability between active smokers, ex-smokers and non-smokers using [123I]FP-CIT (DaTSCAN) and SPECT. *EJNMMI Res.* 2013;3(1):39.
 11. Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. *Eur J Nucl Med Mol Imaging.* 2013;40(2):213–27.
 12. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. *J Nucl Med.* 1995;36(7):1175–81.
 13. Matsutomo N, Nagaki A, Yamao F, Sasaki M. Optimization of iterative reconstruction parameters with 3-dimensional resolution recovery, scatter and attenuation correction in (1)(2)(3)I-FP-CIT SPECT. *Ann Nucl Med.* 2015;29(7):636–42.
 14. Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. *Eur J Nucl Med Mol Imaging.* 2006;33(12):1491–9.
 15. Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. *Pharmacogenomics J.* 2003;3(4):242–7.
 16. Mill J, Asherson P, Browes C, D'Souza U, Craig I. Expression of the dopamine transporter gene is regulated by the 3' UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. *Am J Med Gen.* 2002;114(8):975–9.
 17. Hall FS, Itokawa K, Schmitt A, Moessner R, Sora I, Lesch KP, et al. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. *Neuropharmacology.* 2014;76(Pt A):146–55.
 18. Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. *Brain Journal Neurol.* 2012;135(Pt 9):2798–808.
 19. Kaasinen V, Joutsa J, Nojonen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease. *Neurobiol Aging.* 2015;36(4):1757–63.
 20. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain Journal Neurol.* 1991;114(Pt 5):2283–301.
 21. Rivest R, Falardeau P, Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. *Brain Res.* 1995;692(1–2):269–72.
 22. Tripanichkul W, Jaroensuppaperch EO, Finkelstein DI. Estrogen enhances the number of nigral dopaminergic neurons of adult male mice without affecting nigral neuroglial number and morphology. *Neurosci Lett.* 2008;435(3):210–4.
 23. Yoest KE, Cummings JA, Becker JB. Estradiol, dopamine and motivation. *Cent Nerv Syst Agents Med Chem.* 2014;14(2):83–9.
 24. Moisan F, Kab S, Mohamed F, Canonico M, Le Guern M, Quintin C, et al. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. *J Neurol Neurosurg Psychiatry.* 2016;87(9):952–7.
 25. Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, et al. The impact of reconstruction method on the quantification of DaTSCAN images. *Eur J Nucl Med Mol Imaging.* 2010;37(1):23–35.
 26. Kameiyama H, Matsutomo N, Nagaki A, Yamao F. Effect of reconstruction strategies for the quantification and diagnostic accuracy of (123)I-FP-CIT SPECT. *Nihon Hoshasen Gijutsu Gakkai Zasshi.* 2016;72(7):595–601.